Sandoz is one such company that hopes to offer the NHS savings potential. Its Humira biosimilar, Hyrimoz, could represent savings of more than £250 million a year, according to the company ...
EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
Read Intellectual Property Law updates, alerts, news, and legal analysis from leading lawyers and law firms: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback